Collaboration, License, and Other Agreements - Other Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Disaggregation of Revenue [Line Items]
Acquired in-process research and development	$ 56.2	$ 100.0	$ 87.2	$ 156.1
Sonoma Biotherapeutics, Inc.
Disaggregation of Revenue [Line Items]
Acquired in-process research and development	$ 45.0		$ 45.0	45.0
Alnylam Pharmaceuticals, Inc
Disaggregation of Revenue [Line Items]
Acquired in-process research and development		$ 100.0		$ 100.0

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details